Geron (GERN) to Release Earnings on Wednesday

Geron (NASDAQ:GERN) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $45.29 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Geron Trading Down 7.0 %

NASDAQ:GERN opened at $2.39 on Tuesday. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -7.47 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The business has a fifty day moving average of $3.08 and a 200-day moving average of $3.84.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GERN shares. Barclays upgraded shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Geron in a report on Tuesday, December 10th. Needham & Company LLC boosted their target price on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Finally, B. Riley cut their target price on Geron from $5.50 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.91.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.